Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Isomorphic Labs President Predicts AI Will Design All Drugs

AI summary

Isomorphic Labs President Max Jaderberg said he expects AI eventually to design all drugs, while acknowledging that the timing is uncertain. The company remains in preclinical development and plans to begin its first clinical trial by the end of 2026 to test AI-designed candidates in patients. Its IsoDDE drug-design engine is supported by company-published technical results that have not yet been independently validated.

In-depth insight

Isomorphic Labs’ ambition reflects the potential role of AI in drug discovery, but its preclinical work has not established whether AI-designed candidates are safe or effective in patients.

人类并不擅长造药,AI 将包揽所有药物?近日,AI 制药公司 Isomorphic Labs 的总裁 Max Jaderberg 在英国一场活动上表示,未来所有药物都会由 AI 设计出来,唯一的悬念在于这一未来究竟会以多快的速度到来。

他提到,Isomorphic Labs 目前仍处于药物研发的临床前阶段。按照既定计划,公司预计将在 2026 年年底启动首次临床试验,届时,其 AI 设计的候选药物将开始在真实患者身上接受安全性和有效性的检验。

Isomorphic Labs 是一家备受关注的 AI 制药公司,也是谷歌母公司 Alphabet 旗下的子公司。2021 年,诺奖得主 Demis Hassabis 从 DeepMind 分拆创立了这家公司,总部位于英国伦敦。“Isomorphic”意为“同构”,这一名称也体现了公司的理念:生物学与信息科学之间可能存在某种深层联系。

2026 年 5 月,Isomorphic Labs 完成了高达 21 亿美元的 B 轮融资,创下当时 AI 制药领域单轮融资的最高纪录。Hassabis 兼任该公司的 CEO,Alphabet 则为其提供主要资金支持。Isomorphic Labs 与 DeepMind 有着深厚的渊源,它的成立也是为了将 DeepMind 在 AI 领域的研究成果进一步应用于药物研发。

#Isomorphic Labs#IsoDDE#AlphaFold#AlphaFold 3#Google DeepMind#Alphabet#Eli Lilly#Novartis#Demis Hassabis#Max Jaderberg

Original · 7 min readRead the original
Group chat

No comments yet. Start the conversation.